stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Return on assets
Veracyte, Inc.'s return on assets over the twelve months to 30 September 2026 was 8.63%, up 3.7 percentage points from fiscal 2025 (4.90%). Over the past ten years it has ranged from −48.1% (fiscal 2015) to 4.90% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 4.90% | 2.90 |
| FY2024 | 2.00% | 8.55 |
| FY2023 | −6.55% | (3.43) |
| FY2022 | −3.12% | 6.07 |
| FY2021 | −9.19% | 0.34 |
| FY2020 | −9.53% | (3.16) |
| FY2019 | −6.37% | 16.71 |
| FY2018 | −23.1% | 11.42 |
| FY2017 | −34.5% | 1.08 |
| FY2016 | −35.6% | 12.54 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| BLLN BillionToOne, Inc. compare | 9.02% |
| VCYT Veracyte, Inc. | 8.63% |
| SHC Sotera Health Company compare | 5.28% |
| RDNT RadNet, Inc. compare | −0.55% |
| NEO NeoGenomics, Inc. compare | −2.35% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| GRAL GRAIL, Inc. compare | −15.2% |
| WGS GeneDx Holdings Corp. compare | −22.5% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement